Zolinza Related Clinical Trials
A Phase I/II Clinical Trial of an Experimental Cancer Drug in Combination With an FDA Approved Cancer Drug for Patients With Relapsed/Refractory Non-Small-Cell Lung Cancer [Terminated]
Suberoylanilide Hydroxamic Acid in Advanced Solid Tumors [Active, not recruiting]
Phase I Study of Vorinostat in Combination With Docetaxel in Patients With Advanced and Relapsed Solid Malignancies. [Recruiting]
Vorinostat, Carboplatin and Gemcitabine Plus Vorinostat Maintenance in Women With Recurrent, Platinum-Sensitive Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer [Recruiting]
A Crossover Study to Assess the Effects of Vorinostat (MK0683, SAHA) in Patients With Advanced Cancer [Recruiting]
Vorinostat in Combination With Vinorelbine in Patients With Advanced Cancer [Recruiting]
Phase IIa Vorinostat (MK 0683, SAHA) Study in Lower Risk Myelodysplastic Syndromes [Recruiting]
Proteasome Inhibitor NPI-0052 and Vorinostat in Patients With Non-Small Cell Lung Cancer, Pancreatic Cancer, Melanoma or Lymphoma [Recruiting]
SAHA + CHOP in Untreated T-cell Non-Hodgkin's Lymphoma [Recruiting]
Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant [Recruiting]
A Clinical Trial to Validate Molecular Targets of Vorinostat in Patients With Stage I-III Non-Small Cell Lung Cancer [Recruiting]
A Phase I/II Study of Paclitaxel Plus Carboplatin Plus Vorinostat in Recurrent Ovarian Cancer [Recruiting]
Vorinostat, Isotretinoin and Carboplatin in Adults With Recurrent Glioblastoma Multiforme (GBM) [Recruiting]
Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma [Recruiting]
Vorinostat in Combination With Radiation Therapy and Infusional Fluorouracil (5-FU) in Patients With Locally Advanced Adenocarcinoma of the Pancreas [Recruiting]
Study of the Combination of Vorinostat and Radiation Therapy for the Treatment of Patients With Brain Metastases [Recruiting]
Study of Vorinostat (MK0683), an HDAC Inhibitor, in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma [Recruiting]
Study of Vorinostat (MK0683) an HDAC Inhibitor, or Placebo in Combination With Bortezomib in Patients With Multiple Myeloma [Recruiting]
Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS) [Recruiting]
Lenalidomide, Vorinostat and Dexamethasone in Relapsed Patients With Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL) [Not yet recruiting]
Vorinostat Plus Radiation Therapy in Pancreatic Cancer [Recruiting]
Clinical Trial of SAHA in Patients With Breast Cancer [Recruiting]
Study on Efficacy and Tolerability of Vorinostat in Patients With Advanced, Metastatic STS [Not yet recruiting]
Trial of Vorinostat in Combination With Cyclophosphamide, Etoposide, Prednisone and Rituximab for Elderly Patients With Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) [Recruiting]
Vorinostat and Pegylated Liposomal Doxorubicin in Relapsed or Refractory Lymphomas [Recruiting]
HDAC Inhibitor Vorinostat (SAHA) With Capecitabine (Xeloda) Using a New Weekly Dose Regimen for Advanced Breast Cancer [Recruiting]
Carboplatin and Etoposide in Combination With Vorinostat for Patients With Extensive Stage Small Cell Lung Cancer [Recruiting]
Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors [Active, not recruiting]
Phase II Study of Idarubicin, Cytarabine, and Vorinostat With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML) [Recruiting]
Vorinostat in Combination With Palliative Radiotherapy for Patients With Non-Small Cell Lung Cancer [Recruiting]
Vorinostat and Idarubicin in Treating Patients With Relapsed or Refractory Leukemia or Myelodysplastic Syndromes [Recruiting]
Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced NSCLC [Recruiting]
Suberoylanilide Hydroxamic Acid in Treating Patients With Relapsed Non-Hodgkin's Lymphoma [Active, not recruiting]
Vorinostat, Irinotecan, Fluorouracil, and Leucovorin in Treating Patients With Advanced Upper Gastrointestinal Cancer [Recruiting]
Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin's Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia [Recruiting]
Compassionate Use of Vorinostat (MK0683, SAHA) for the Treatment of Patients With Advanced Cutaneous T-Cell Lymphoma [Recruiting]
Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction [Recruiting]
Vorinostat and Gemtuzumab in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia [Recruiting]
Vorinostat in Treating Patients With Locally Recurrent or Metastatic Cancer of the Urothelium [Active, not recruiting]
Vorinostat, Paclitaxel, and Radiation Therapy in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed by Surgery [Recruiting]
Continuation Clinical Trial of Oral L-0010790038 in Advanced Cancer [Recruiting]
An Investigational Study of a Histone Deacetylase (HDAC) Inhibitor Plus Targretin in Cutaneous T-Cell Lymphoma Patients [Active, not recruiting]
Vorinostat and Doxorubicin in Treating Patients With Metastatic or Locally Advanced Solid Tumors [Recruiting]
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Relapsed or Refractory Breast, Colorectal and Non-Small Cell Lung Cancer [Terminated]
Vorinostat and Trastuzumab in Treating Patients With Metastatic or Locally Recurrent Breast Cancer
Carboplatin, Paclitaxel, Bevacizumab and Vorinostat for Patients With Advanced Non-Small Cell Lung Cancer [Recruiting]
Study of Vorinostat (MK0683, SAHA) in Combination With Bortezomib in Patients With Advanced Multiple Myeloma [Recruiting]
Vorinostat, Paclitaxel, and Bevacizumab in Treating Patients With Metastatic Breast Cancer and/or Breast Cancer That Has Recurred in the Chest Wall and Cannot be Removed by Surgery [Recruiting]
Vorinostat and Azacitidine in Treating Patients With Myelodysplastic Syndromes or Acute Myeloid Leukemia [Recruiting]
Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme [Not yet recruiting]
A Study to Evaluate the Use of the Drug Combination Vorinostat, Niacinamide, and Etoposide in Patients With Lymphoid Malignancies That Have Reoccurred [Recruiting]
Vorinostat (MK0683, SAHA) Versus Placebo in Advanced Malignant Pleural Mesothelioma [Recruiting]
Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders [Recruiting]
Vorinostat in Treating Patients With Progressive Metastatic Prostate Cancer
Phase I Trial of Vorinostat (MK0683, SAHA) in Combination With Decitabine in Patients With AML or MDS [Recruiting]
Vorinostat in Treating Women Who Are Undergoing Surgery For Newly Diagnosed Stage I, Stage II, or Stage III Breast Cancer [Recruiting]
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
Suberoylanilide Hydroxamic Acid in Treating Patients With Progressive Stage IV Breast Cancer
Vorinostat and Bevacizumab in Treating Patients With Unresectable or Metastatic Kidney Cancer
Suberoylanilide Hydroxamic Acid in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer [Recruiting]
Vorinostat in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Vorinostat in Treating Patients With Recurrent or Persistent Ovarian Epithelial or Primary Peritoneal Cavity Cancer
Vorinostat (MK0683, SAHA) + Revlimid + Dexamethasone in Multiple Myeloma [Recruiting]
Suberoylanilide Hydroxamic Acid, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Progressive Metastatic or Unresectable Colorectal Cancer or Other Solid Tumors [Recruiting]
Phase I/II of Oral Vorinostat Combination With Erlotinib in NSCLC Patients With EGFR Mutations With DP After Erlotinib. [Recruiting]
Vorinostat and Temozolomide in Treating Patients With Malignant Gliomas [Recruiting]
A Clinical Trial of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Advanced Multiple Myeloma [Terminated]
A Clinical Trial of Vorinostat (MK0683, SAHA) in Combination With FDA Approved Cancer Drugs in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) [Recruiting]
Vorinostat and Low Dose Cytarabine for High Risk Myelodysplasia [Recruiting]
Phase II Trial of SAHA & Tamoxifen for Patients With Breast Cancer [Recruiting]
Trial for Locally Advanced Her2 Positive Breast Cancer Using Paclitaxel, Trastuzumab, Doxorubicin and Cyclophasmide on a Weekly Basis [Recruiting]
Vorinostat in Treating Patients With Acute Myeloid Leukemia [Suspended]
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer [No longer recruiting]
Vorinostat in Treating Patients With Relapsed or Refractory Advanced Hodgkin's Lymphoma [Active, not recruiting]
A Phase I Trial of Vorinostat in Combination With Bevacizumab & Irinotecan in Recurrent Glioblastoma [Recruiting]
Vorinostat and Rituximab in Treating Patients With Indolent Non-Hodgkin Lymphoma [Recruiting]
Vorinostat and Isotretinoin in Treating Patients With Advanced Kidney Cancer [Recruiting]
Vorinostat and Flavopiridol in Treating Patients With Advanced Solid Tumors [Recruiting]
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma [Recruiting]
Phase I Vorinostat + Sorafenib in Patients With Advanced Solid Tumors [Recruiting]
Vorinostat and Decitabine in Treating Patients With Relapsed, Refractory, or Poor-Prognosis Hematologic Cancer or Other Diseases [Recruiting]
Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Primary Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma [Recruiting]
Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma [Recruiting]
Vorinostat, Cladribine, and Rituximab in Treating Patients With Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, or Relapsed B-Cell Non-Hodgkin Lymphoma [Recruiting]
Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma [Recruiting]
Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer [Recruiting]
Study of Oral Vorinostat in Combination With Topotecan in Patients With Chemosensitive Recurrent Small Cell Lung Cancer (SCLC) [Not yet recruiting]
Vorinostat After Stem Cell Transplant in Treating Patients With High-Risk Lymphoma [Recruiting]
Carboplatin and Paclitaxel With or Without Vorinostat in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer [Recruiting]
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme [Recruiting]
Vorinostat and IV Fluorouracil/Leucovorin (5FU/LV) in Patients With Metastatic Colorectal Cancer [Recruiting]
Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma [Recruiting]
Flavopiridol and Vorinostat in Treating Patients With Relapsed or Refractory Acute Leukemia or Chronic Myelogenous Leukemia or Refractory Anemia [Recruiting]
Vorinostat and Lenalidomide After Autologous Stem Cell Transplant in Treating Patients With Persistent Multiple Myeloma [Recruiting]
Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy [No longer recruiting]
Carboplatin and Paclitaxel Albumin-Stabilized Nanoparticle Formulation With or Without Vorinostat in Treating Women With Breast Cancer That Can Be Removed by Surgery [Recruiting]
Vorinostat in Treating Patients With Kidney Cancer [Recruiting]
Oral SAHA (Suberoylanilide Hydroxamic Acid) in Advanced Cutaneous T-Cell Lymphoma [Completed]
Vorinostat and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors [Recruiting]
Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors [Recruiting]
An Investigational Drug Study With Suberoylanilide Hydroxamic Acid in Relapsed Diffuse Large B-Cell Lymphoma [No longer recruiting]
|
